NCT02013531View on ClinicalTrials.gov

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

June 30, 2014

Conditions
Major Depressive DisorderAnxiety
Interventions
DRUG

Brexpiprazole

Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally

Trial Locations (21)

10168

New York

10305

Staten Island

18104

Allentown

21208

Baltimore

23230

Richmond

30308

Atlanta

32256

Jacksonville

32607

Gainesville

33145

Miami

47905

Lafayette

48307

Rochester Hills

76012

Arlington

78731

Austin

85712

Tuscon

92056

Oceanside

92591

Temecula

92845

Garden Grove

97301

Salem

02131

Boston

01830

Haverhill

05091

Woodstock

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY